8-K: Certara Reports Strong Q3 2024 Results Driven by Biosimulation Software Growth

Certara's third quarter results show an 11% revenue increase year-over-year, driven by strong growth in biosimulation software and services.

Summary

• Certara reported a total revenue of $94.8 million for the third quarter of 2024, an 11% increase compared to $85.6 million in the same period last year.
• Software revenue grew by 15% to $35.9 million, while services revenue increased by 9% to $58.9 million.
• The company's net loss significantly improved to $1.4 million, compared to a $49.0 million loss in the third quarter of 2023, primarily due to a decrease in goodwill impairment expense.
• Adjusted EBITDA rose by 15% to $33.1 million, up from $28.8 million in the prior year's third quarter.
• Total bookings for the quarter were $96.1 million, a 13% increase year-over-year, with software bookings up 28% and services bookings up 6%.
• Certara has updated its full-year 2024 outlook, projecting revenue between $380 million and $385 million, adjusted EBITDA between $120 million and $124 million, and adjusted diluted earnings per share between $0.41 and $0.44.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved profitability, and increased bookings, particularly in the software segment. The updated full-year guidance also indicates confidence in future performance. However, there are some concerns about the services business and cautious spending by large biopharma customers.

Positives

• The company experienced strong growth in its biosimulation software portfolio.
• There was a significant reduction in net loss due to decreased goodwill impairment expense.
• Adjusted EBITDA showed a healthy increase, indicating improved profitability.
• Software bookings saw substantial growth, suggesting strong future revenue potential.
• The company is actively managing its expense structure to support demand for core biosimulation software and services.
• The updated full-year outlook indicates positive expectations for revenue, adjusted EBITDA, and adjusted diluted earnings per share.

Negatives

• The services business experienced mixed results, with weaker performance in regulatory services offsetting growth in biosimulation services.
• The company noted cautious spending among large biopharma customers impacting services growth.
• Total cost of revenue increased due to employee-related expenses and software amortization.
• Cash and cash equivalents decreased from $272.3 million to $233.0 million year-over-year.

Risks

• The company faces risks related to competition within its market and the acceptance of model-informed biopharmaceutical discovery.
• Changes or delays in government regulations could impact the business.
• Economic conditions, including inflation and currency exchange fluctuations, pose potential challenges.
• Delays or cancellations in customer projects due to supply chain issues or clinical trial delays could affect revenue.
• The company is exposed to risks related to the use of artificial intelligence and machine learning in its products and services.
• There are risks associated with the company's ability to retain key personnel and manage a global business.

Future Outlook

Certara updated its 2024 outlook, expecting full-year revenue between $380 million and $385 million, adjusted EBITDA between $120 million and $124 million, and adjusted diluted earnings per share between $0.41 and $0.44. Fully diluted shares are expected to be in the range of 160 million to 162 million.

Management Comments

• Certara's results demonstrated strength in biosimulation software and services which are the result of our continued investment in biosimulation, said William F. Feehery, Chief Executive Officer.
• Following the close of the Chemaxon transaction, we are focused on integrating our software capabilities to generate a best-in-class, lab-to-clinic biosimulation platform, said William F. Feehery, Chief Executive Officer.
• We are pleased with the growth in our software business, said John Gallagher, Chief Financial Officer.
• Our services business was mixed, with biosimulation services growing 13% offset by weaker performance in our regulatory services business, said John Gallagher, Chief Financial Officer.
• In the second half of the year, we will continue to diligently manage our expense structure to support demand for core biosimulation software and services, said John Gallagher, Chief Financial Officer.

Industry Context

The results reflect a growing trend in the pharmaceutical industry towards adopting model-informed drug development, with Certara's biosimulation software and services playing a key role. The company's focus on integrating its software capabilities following the Chemaxon transaction positions it to capitalize on this trend.

Comparison to Industry Standards

• Certara's 15% growth in software revenue is strong compared to other software providers in the life sciences sector, such as Veeva Systems, which reported a 16% growth in subscription revenue in their most recent quarter.
• The 13% growth in biosimulation services is also notable, as many CROs (Contract Research Organizations) are seeing slower growth in their services divisions due to cautious spending by large biopharma companies.
• Certara's adjusted EBITDA margin of approximately 35% is competitive with other established software and services companies in the healthcare technology space, such as Medidata Solutions, which has a similar margin profile.
• The company's focus on biosimulation aligns with the industry's increasing emphasis on using advanced modeling and simulation techniques to accelerate drug development, similar to companies like Simulations Plus, which also specialize in this area.

Stakeholder Impact

• Shareholders will likely view the improved financial results and positive outlook favorably.
• Employees may benefit from the company's growth and continued investment in biosimulation.
• Customers will have access to an integrated biosimulation platform, potentially improving their drug development processes.
• Suppliers and creditors may see increased business opportunities due to the company's growth.

Next Steps

• Certara will continue to focus on integrating its software capabilities following the Chemaxon transaction.
• The company will diligently manage its expense structure to support demand for core biosimulation software and services.
• Certara will host a conference call on November 6, 2024, to discuss its third quarter 2024 financial results.

Key Dates

Keywords

biosimulation, software, revenue, EBITDA, drug development, financial results, bookings, pharmaceutical, biopharma, Pinnacle 21